Artivion (AORT) vs Bio-Rad Laboratories (BIO.B)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed Artivion (AORT) over the past year, gaining 28.2% versus a loss of 46.7%. Over five years, AORT leads with a +1.2% price change compared with -50.5% for BIO.B. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $1.04 billion), about 9.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AORT | BIO.B |
|---|---|---|
| Share price | $21.24 | $365.08 |
| Market cap | $1.04B | $9.76B |
| 1-day change | -1.71% | 0.00% |
| YTD return | -52.62% | +17.50% |
| 1-year return | -46.66% | +28.15% |
| 5-year return | +1.17% | -50.54% |
| P/E ratio (TTM) | — | 46.27 |
| Forward P/E | 28.38 | — |
| EPS (TTM) | $-0.07 | $7.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.58B |
| Revenue growth (YoY) | — | +0.65% |
| Net income (latest FY) | — | $759.90M |
| Gross margin | — | 51.87% |
| Operating margin | — | 1.83% |
| Net margin | — | 29.42% |
| 52-week high | $48.25 | $365.08 |
| 52-week low | $19.16 | $244.54 |
| Distance from 52-week high | -55.98% | 0.00% |
| Analyst consensus | none | — |
| Avg. price target upside | +98.45% | — |
| Average volume | 634.11K | 6 |
| Shares outstanding | 48.76M | 5.06M |
| Employees | 1,800 | 7,450 |
| Sector | Health Care | Healthcare |
| Industry | Medical/Dental Instruments | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 9.4 times larger than Artivion by market value ($9.76B vs $1.04B).
- BIO.B has outperformed AORT by 74.8 percentage points over the past year.
- The two companies sit in different sectors: Artivion in Health Care and Bio-Rad Laboratories in Healthcare.
About Artivion
AORT stock →Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Health Care · Medical/Dental Instruments · 1,800 employees
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
AORT vs BIO.B FAQ
Which is bigger, Artivion or Bio-Rad Laboratories?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $1.04B for Artivion (AORT).
Which stock has performed better over the past year, AORT or BIO.B?
BIO.B returned +28.15% over the past 12 months, compared with -46.66% for AORT (price return, excluding dividends). Past performance does not predict future results.
Are Artivion and Bio-Rad Laboratories in the same industry?
No. Artivion is in the Health Care sector, while Bio-Rad Laboratories is in Healthcare.